The 15 most recent market catalysts affecting $DMED, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides
DataMEDS AI announced that its Corexa Pharmacy unit has successfully made its first commercial sale of compounded peptides. This is significant because it demonstrates the company'…
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 65
DataMEDS AI Terminates Second Amended and Restated Letter of Intent with Datavault AI and Other Parties
DataMEDS AI terminated its Second Amended and Restated Letter of Intent (2nd LOI) with multiple entities, including Datavault AI and REBOOT Health AI, citing 'market conditions.' T…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
DataMEDS AI (formerly Wellgistics Health, Inc.) has announced a non-binding Memorandum of Understanding (MOU) with a Florida-based HMO to implement its 'Health Lives Here' GLP-1 pa…
Nov 4, 2026
Corporate Catalyst
Bearish
Impact 65
DataMeds AI Terminates Letter of Intent with Datavault AI
DataMeds AI terminated its second amended and restated letter of intent with Datavault AI, citing 'market conditions.' This is significant because it cancels a previously planned s…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 55
DataMeds AI, Inc. Regains Compliance With NASDAQ Listing Standards
DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) has successfully regained compliance with NASDAQ listing standards. This is significant because it eliminates the immediate th…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 85
DataMeds AI shares are trading higher after the company announced it entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI
This headline signals a significant corporate catalyst for DataMeds AI, driving its shares higher. The Intellectual Property License and Product and Services Agreement with REBOOT …
Oct 16, 2026
Corporate Catalyst
Neutral
Impact 65
DataMeds AI Enters IP License Agreement With Reboot Health AI On Oct 13, 2026; Reboot Grants DataMeds AI Exclusive License To Patents And Health AI Platform In U.S.; Reboot To Receive Portion Of DataMeds AI's Adj Gross Revenue; Co To Issue Reboot 666,667 Shares As IP License Stock Component
DataMeds AI has secured an exclusive license to REBOOT Health AI's platform for managing GLP-1 users in the US direct-to-consumer market. This is a significant strategic move for D…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 75
DataMeds AI shares are trading higher after the company announced its subsidiary Helomics has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx Assay.
The Medicaid coverage determination for the ChemoFx Assay is a substantial positive for DataMeds AI. It significantly broadens the addressable market for this diagnostic tool, part…
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 75
DataMeds AI shares are trading higher after the company announced the launch of its Health Lives Here mobile application, a joint initiative with Tollo Health and the NFL Alumni Association.
This headline represents a significant corporate catalyst for DataMeds AI, as a new product launch, especially one involving strategic partnerships, can be a major growth driver. T…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
DataMeds AI shares are trading higher after the company announced it settled litigation related to outstanding debt and receivables related to the May 11, 2023 Wellgistics Membership Purchase Interest Agreement.
The settlement of litigation related to outstanding debt and receivables is a significant positive catalyst for DataMeds AI. Legal disputes, especially those involving financial ob…
Sep 17, 2026
Market Technicals
Bearish
Impact 75
DataMeds AI Shares Halted On Circuit Breaker To The Downside, Stock Now Down -4.61%
The circuit breaker halt on DataMeds AI shares signifies extreme selling pressure, likely triggered by negative news or a significant shift in investor sentiment. While specific to…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
DataMEDS AI shares are trading higher after Axe Compute announced the sale of its legacy AI cancer diagnostics laboratory business, Helomics, to DataMEDS in an all‑stock transaction.
This headline represents a significant corporate catalyst for DataMEDS AI, as the acquisition of Helomics is likely to be accretive to its AI cancer diagnostics business, expanding…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 55
DataMeds AI Announces Completion Of Subsidiary Name Changes To Corexa Pharmacy, Corexa Tech & Hub Under Renamed Corexa Health Division
The renaming of subsidiaries and the creation of a new division suggest a strategic realignment for DataMeds AI. This move aims to streamline operations, enhance brand recognition …
Jul 31, 2026
Corporate Catalyst
Neutral
Impact 65
DataMeds AI's Corexa Pharmacy Begins Direct-To-Consumer Distribution Of Tollovid And Galactovid
DataMeds AI, through its Corexa Pharmacy subsidiary, is initiating direct-to-consumer distribution of Tollovid and Galactovid, products from Tollo Health. This is significant becau…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 75
DataMeds AI shares are trading lower after amending its agreement with Datavault AI to expand PharmacyChain licensing beyond distribution into broader healthcare and wellness applications.
This headline indicates a corporate catalyst for DataMeds AI, with the immediate market reaction being negative. The expansion of the PharmacyChain licensing agreement beyond distr…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.